insulin glargine + prandial rapid-acting insulin analogue

This drug is a **combination therapy** comprising **insulin glargine**, a long-acting basal insulin analogue, and a **prandial rapid-acting insulin analogue** (such as insulin lispro, aspart, or glulisine). Insulin glargine provides a continuous, smooth, peakless supply of insulin over approximately 24 hours, mimicking physiological basal insulin secretion. The rapid-acting prandial analogue supplies bolus insulin coverage for meal-related (prandial) glucose excursions, closely imitating endogenous prandial insulin release. This combination is foundational to the **basal-bolus regimen** for patients with type 1 and type 2 diabetes who require intensive insulin therapy, providing flexibility, improved glycemic control (as measured by reductions in HbA1c), and a lower risk of hypoglycemia compared to some older regimens[1][2][3][4][7].\nInsulin glargine was originally developed by Aventis Pharma (now Sanofi), and the various rapid-acting insulin analogues are developed and marketed by multiple companies.\nCommon clinical use is in the management of **type 1 diabetes** (absolute insulin deficiency) and **type 2 diabetes** when advanced disease or insulin deficiency requires both continuous basal and meal-time insulin coverage[1][3][4][7].

Brand names

Lantus

Other names

MDIMultiple daily injections using insulin glargine + rapid acting analog